BioNTech SE (Nasdaq: BNTX) has terminated the Phase II BNT122-01 trial of autogene cevumeran in resected colorectal cancer after an independent data safety monitoring board identified a numerical imbalance in overall survival between treatment arms, closing off the drug's most advanced application in a tumor type that has historically resisted immunotherapy.
The trial, conducted in consultation with Genentech, a member of the Roche Group, enrolled patients with circulating tumor DNA (ctDNA)-positive, surgically resected Stage II (high risk) or Stage III colorectal cancer (CRC) and compared autogene cevumeran as adjuvant monotherapy against watchful waiting. The independent Data Safety Monitoring Board (DSMB) had previously crossed the futility boundary in October 2025, at which point it concluded data were insufficiently mature to draw reliable efficacy conclusions and did not object to continuation. In its most recent review, however, the DSMB found that further continuation was unlikely to change the efficacy outcome and recommended stopping the trial. No new safety signals were identified.
Autogene cevumeran is an individualized mRNA-based neoantigen-specific immunotherapy that encodes patient-specific tumor neoantigens identified through tumor sequencing, training T cells to recognize and attack residual cancer cells. The monotherapy design in BNT122-01 was a deliberate test of whether the vaccine alone — without checkpoint inhibitor support — could prevent recurrence in a ctDNA-positive, molecularly selected population.
The failure reflects a fundamental immunological challenge. CRC is predominantly microsatellite stable (MSS/pMMR), a tumor subtype with low mutational burden and an immunosuppressive microenvironment that has consistently resisted checkpoint inhibition. The numerical OS imbalance, which media reports indicate favored the control arm, raises a more concerning efficacy signal than futility alone, although BioNTech has not disclosed the magnitude, statistical significance, or causes of the imbalance. Full trial data will be shared with the scientific community at a future date.
The termination is a setback for the specific strategy of using ctDNA positivity to select resected CRC patients for adjuvant autogene cevumeran monotherapy. No approved therapy currently targets the ctDNA-positive adjuvant CRC population specifically; standard care remains oxaliplatin-based chemotherapy (FOLFOX or CAPOX) for Stage III and high-risk Stage II disease. Roche's Tecentriq (atezolizumab) plus mFOLFOX6 has a PDUFA date of October 9, 2026 for adjuvant Stage III dMMR/MSI-H colon cancer — a biomarker-defined subgroup representing approximately 15% of Stage III CRC — but that program does not address the MSS majority.